TINUBU-SQUARE
21.1.2021 13:02:12 CET | Business Wire | Press release
Tinubu Square, the market leader for enterprise software solutions to Credit and Surety Insurers, announces cooperation with Microsoft, the leading provider in Business Intelligence solutions.
Olivier Placca , Tinubu Square co-founder and Deputy CEO declares: “This cooperation is strategic for Tinubu Square to continue to offer carriers best-in-class technologies in the long run using the strength of Power BI across all business lines of our SaaS-based, end-to-end Enterprise Solution Platform. Our primary objective is answering our customers’ needs. Integrating Power BI to our Credit Insurance and Surety Platform offers them key benefits such as powerful insights, a scalable solution and settings on-the-fly. To take full advantage of our Business Intelligence capabilities, customers can tailor their own reports using a specifically designed Tinubu® CIS data model, increasing efficiency and data relevance.
Offer Sadey , Chief Technical Officer at Tinubu Square, explains: “Before choosing Microsoft, we ran through a market research with full technical assessment of the different offerings. We wanted to be sure to integrate the best solution for our customers’ benefit. It had to perfectly fit our own solutions and enhance them; we found that Microsoft Power BI was the right technology for achieving that end.
Today, Power BI is integrated in both our Trade Credit Insurance and our Surety SaaS Solutions (Tinubu® CIS & Tinubu® eSURETY®). Choosing Power BI brings the assurance of benefiting from the best technical tool. It is scalable to the customer’s business needs and is highly secured. It has a strong API enabling carriers to personalize the whole configuration of the reports they need and customize their different workspaces. Configuration is actually very easy and can be done on-the-go. Customers can also connect to the Data Warehouse for their own needs of data analysis and prediction.
Another advantage is the cost; Power BI is very affordable and allows us to continue offering high-end technological services while remaining cost-competitive.
Overall, this collaboration with Microsoft is built on a solid policy: a progressive licensing mode and a strong global support – technical, legal and business - allowing rapid scalability and therefore growth for our customers.”
Patrice Amann
, Senior Director, Financial Services Business Lead - EMEA, at Microsoft expresses: “Being at the vanguard of technological innovations, Microsoft developed Power BI which is specifically designed to facilitate businesses’ strategic decisions and growth.
Today, business forecasts and decision-making processes rely solely on the quality of data, transformed into knowledge, and their real-time availability. Every company is looking for the guaranty that their data and cloud services will be fully secured and supported at all time, whether their activities spread on a global scale or is purely local.”
He adds: “This collaboration with Tinubu Square shows that Microsoft Business Intelligence solutions are also designed to perfectly adjust to and match the need for digitalization in the Credit Insurance and Surety industry. Our goal is to provide the necessary technology to contribute to the large success of Tinubu Square’s specialized solutions for carriers, and this cooperation materializes a joint intention between both companies to answer exact business needs and provide an always optimized customer experience.”
About Tinubu Square
– www.tinubu.com
— @TinubuGroup
Tinubu Square is the industry-leading SaaS platform vendor, enabling Credit Insurance & Surety digital transformation. For 20 years, Tinubu Square has provided Credit & Surety insurers across the globe with software and services allowing them to offer best-in-class customer experience, as well as significantly reduce their exposure to risk and their financial, operational and technical costs. Tinubu Square has an international footprint with customers in over 20 countries, including 30 of the top 60 worldwide Credit & Surety underwriters.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210121005461/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom